Results 231 to 240 of about 91,755 (270)

Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal-Cell Carcinoma [PDF]

open access: yesNew England Journal of Medicine, 2018
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell ...
Nizar Tannir   +2 more
exaly   +5 more sources

Nivolumab

Drugs of Today, 2014
Until recently, a treatment for advanced melanoma with a tolerable side effect profile has remained elusive. Therefore, despite its relatively rare occurrence, melanoma continues to cause the majority of skin cancer deaths, with less than 15% of those affected with late-stage disease surviving 10 years or more.
E, Fulchiero, A, Jimeno
openaire   +2 more sources

Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma [PDF]

open access: yesNew England Journal of Medicine, 2019
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.
Lars Bastholt   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy